Should states launch clinical trials for repurposed drugs that may help treat cancers?
15 votes|10 arguments|0 source
73%11
·
Off-patent drugs with promising signals are abandoned because no company can profit. Public trials are the only way to evaluate them rigorously. @@yes_1
Repurposed drugs are cheap and have known safety profiles. Even modest efficacy gains would deliver huge population health value. @@yes_2
Patient-led initiatives (e.g. ReDO, Care Oncology) have surfaced promising signals that need a state-funded confirmatory trial. @@yes_3
Polling consistently shows a majority of citizens support moving forward — democratic legitimacy is on this side. @@yes_4
Pilot programs in comparable jurisdictions have produced encouraging results that opponents tend to downplay or ignore. @@yes_5
13%2
·
Public budgets are tight and existing oncology pipelines already crowded. Funding repurposing risks diverting resources from higher-impact research. @@no_1
Most promising preclinical signals fail in rigorous Phase III. Funding many repurposing trials risks low yield for the money. @@no_2
Designing a rigorous trial for an old drug is harder than it sounds — placebo control, dosing, endpoints all require fresh work. @@no_3
Once enacted, this kind of policy is politically very hard to reverse — that asymmetry alone calls for caution. @@no_4
The evidence base remains contested, and headline studies often haven't been independently replicated at scale. @@no_5
13%2